Spero Therapeutics ( (SPRO) ) has released its Q2 earnings. Here is a breakdown of the information Spero Therapeutics presented to its investors.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Spero Therapeutics, headquartered in Cambridge, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing novel treatments for rare diseases and multi-drug resistant bacterial infections.
In its latest earnings report, Spero Therapeutics announced significant progress in its Phase 3 PIVOT-PO trial for tebipenem HBr, an investigational oral antibiotic for complicated urinary tract infections. The trial was stopped early due to efficacy, and the company plans to submit data to the FDA later this year.
Financially, Spero reported a net loss of $1.7 million for the second quarter of 2025, a significant improvement from the $17.9 million loss in the same period last year. The company saw an increase in total revenue to $14.2 million, primarily driven by collaboration revenue from GSK. Research and development expenses decreased significantly due to reduced clinical expenses related to the PIVOT-PO trial, while general and administrative expenses saw a slight increase.
Spero’s cash position remains strong, with existing funds and milestone payments from GSK expected to support operations into 2028. The company has adjusted its potential commercial milestone payments contingent upon first sales, reflecting the early completion of the PIVOT-PO trial.
Looking ahead, Spero Therapeutics is poised to advance its strategic initiatives, with a focus on regulatory submissions and potential commercialization of tebipenem HBr. The company’s management remains committed to addressing unmet medical needs and enhancing shareholder value through its innovative pipeline and strategic partnerships.